Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

Renu R. Bahadoer , Esmée A. Dijkstra , Boudewijn van Etten , Renu R. Bahadoer , Esmée A. Dijkstra , Boudewijn van Etten , Corrie A.M. Marijnen , Hein Putter , Elma Meershoek‐Klein Kranenbarg , Annet G.H. Roodvoets , Irıs D. Nagtegaal , Regina G. H. Beets‐Tan , Lennart K. Blomqvist , Tone Fokstuen , Albert J. ten Tije , Jaume Capdevila , Mathijs P. Hendriks , Ibrahim Edhemović , Andrés Cervantes , Per J. Nilsson , Bengt Glimelius , Cornelis J.�H. van de Velde , Geke A.P. Hospers , Lars Østergaard , Frank Svendsen Jensen , Per Pfeiffer , K.E.J. Jensen , Mathijs P. Hendriks , Wilhelmina H. Schreurs , H.P. Knol , Hans van Vliet , Jurriaan B. Tuynman , A. Bruynzeel , Emile D. Kerver , Sebastiaan Festen , Monique E. van Leerdam , Geerard L. Beets , L. Dewit , C.J.A. Punt , Pieter J. Tanis , Elisabeth D. Geijsen , Peter Nieboer , Wim Bleeker , Albert J. ten Tije , Rogier M. P. H. Crolla , Addy C.M. van de Luijtgaarden , Jan Willem T. Dekker , J.M. Immink , Frank J. Jeurissen , Andreas Marinelli , Heleen M. Ceha , Tanja C. Stam , P. Quarles an Ufford , Willem H. Steup , Alex L.T. Imholz , R.J.I. Bosker , Jasper Bekker , G.J. Creemers , Grard A. P. Nieuwenhuijzen , Henk van den Berg , Wendy M. van der Deure , Roderick F. Schmitz , Johan M. van Rooijen , Annette F. T. Olieman , A.C.M. van den Bergh , Derk Jan A. de Groot , Klaas Havenga , Jannet C. Beukema , Jacob D. de Boer , Peter H.J.M. Veldman , Ester Siemerink , J.W.P. Vanstiphout , B. De Valk , Q. A. J. Eijsbouts , M. Polée , Christiaan Hoff , Annerie Slot , H.W. Kapiteijn , Koen Peeters , Femke P. Peters , P.A. Nijenhuis , Sandra A. Radema , Hans De Wilt , Pètra M. Braam , G.J. Veldhuis , Daniël A. Hess , Tom Rozema , O. Reerink , Daan ten Bokkel Huinink , A. Pronk , Josephine M. I. Vos , Metin Tascilar , Gijs A. Patijn , Christian Kersten , Odd Mjåland , Marianne G. Guren , Arild Nesbakken , Janez Benedik , Ibrahim Edhemović , Vaneja Velenik , Jaume Capdevila , Eloy Espín , Ramón Salazar
2020 The Lancet Oncology 1,432 citations

Abstract

Systemic relapses remain a major problem in locally advanced rectal cancer. Using short-course radiotherapy followed by chemotherapy and delayed surgery, the Rectal cancer And Preoperative Induction therapy followed by Dedicated Operation (RAPIDO) trial aimed to reduce distant metastases without compromising locoregional control. Between June 21, 2011, and June 2, 2016, 920 patients were enrolled and randomly assigned to a treatment, of whom 912 were eligible (462 in the experimental group; 450 in the standard of care group). Median follow-up was 4·6 years (IQR 3·5-5·5). At 3 years after randomisation, the cumulative probability of disease-related treatment failure was 23·7% (95% CI 19·8-27·6) in the experimental group versus 30·4% (26·1-34·6) in the standard of care group (hazard ratio 0·75, 95% CI 0·60-0·95; p=0·019). The most common grade 3 or higher adverse event during preoperative therapy in both groups was diarrhoea (81 [18%] of 460 patients in the experimental group and 41 [9%] of 441 in the standard of care group) and neurological toxicity during adjuvant chemotherapy in the standard of care group (16 [9%] of 187 patients). Serious adverse events occurred in 177 (38%) of 460 participants in the experimental group and, in the standard of care group, in 87 (34%) of 254 patients without adjuvant chemotherapy and in 64 (34%) of 187 with adjuvant chemotherapy. Treatment-related deaths occurred in four participants in the experimental group (one cardiac arrest, one pulmonary embolism, two infectious complications) and in four participants in the standard of care group (one pulmonary embolism, one neutropenic sepsis, one aspiration, one suicide due to severe depression). The observed decreased probability of disease-related treatment failure in the experimental group is probably indicative of the increased efficacy of preoperative chemotherapy as opposed to adjuvant chemotherapy in this setting. Therefore, the experimental treatment can be considered as a new standard of care in high-risk locally advanced rectal cancer. Dutch Cancer Foundation, Swedish Cancer Society, Spanish Ministry of Economy and Competitiveness, and Spanish Clinical Research Network.

Keywords

MedicineTotal mesorectal excisionRadiation therapyColorectal cancerChemoradiotherapySurgeryStage (stratigraphy)Clinical endpointChemotherapyRandomized controlled trialCancerInternal medicine

MeSH Terms

AdenocarcinomaAgedAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyAdjuvantDigestive System Surgical ProceduresDisease ProgressionDose FractionationRadiationEuropeFemaleHumansMaleMiddle AgedNeoadjuvant TherapyNeoplasm RecurrenceLocalNeoplasm StagingRectal NeoplasmsTime FactorsTreatment FailureUnited States

Related Publications

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the add...

2020 The Lancet 1658 citations

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study

The role of chemoradiation with systemic chemotherapy compared with chemotherapy alone in locally advanced pancreatic cancer (LAPC) is uncertain. One hundred and nineteen patien...

2008 Annals of Oncology 681 citations

Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

Purpose Single-agent gemcitabine (GEM) is standard treatment of metastatic pancreatic cancer. Fixed-dose rate (FDR) GEM and GEM plus oxaliplatin have shown promise in early clin...

2009 Journal of Clinical Oncology 423 citations

Publication Info

Year
2020
Type
article
Volume
22
Issue
1
Pages
29-42
Citations
1432
Access
Closed

Citation Metrics

1432
OpenAlex
61
Influential
1243
CrossRef

Cite This

Renu R. Bahadoer, Esmée A. Dijkstra, Boudewijn van Etten et al. (2020). Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. The Lancet Oncology , 22 (1) , 29-42. https://doi.org/10.1016/s1470-2045(20)30555-6

Identifiers

DOI
10.1016/s1470-2045(20)30555-6
PMID
33301740

Data Quality

Data completeness: 90%